Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

Posted: May 2, 2022 at 2:43 am

Allschwil, Switzerland & Radnor, PA, US – May 2, 2022Idorsia Ltd (SIX: IDIA) & Idorsia Pharmaceuticals, US Inc. today announced that QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are now commercially available for adult patients with insomnia, which is characterized by trouble with falling or staying asleep.

See the rest here:
Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

Related Posts